336 million yuan!

In recent years, with the continuous advancement of medical reform, the profits of pharmaceutical companies have been affected, and they are all looking for new profit growth points
.
Because public hospitals have good cash flow, stable performance growth, strong regional market exclusivity, and strong anti-cyclical advantages, they have become a hot resource for capital
.
Recently, Guizhou Yibai Pharmaceutical issued the "Announcement on the Acquisition of 70% Equity in Deyang Tumor Hospital Co.
, Ltd.
"
.
According to the announcement, Yibai Pharmaceutical intends to acquire a 70% stake in Deyang Cancer Hospital Co.
, Ltd.
jointly held by Foji Medical Management, Foming Medical Management and Foxiang Medical Management for 336 million yuan
.
After the completion of this acquisition, Deyang Cancer Hospital will become its holding subsidiary
.
For this acquisition, Yibai Pharmaceutical believes that oncology medical services are the core business of its medical services, and Deyang Cancer Hospital’s main business is oncology-related characteristic medical services, which is an expansion of its medical service business section
.
After the completion of this transaction, its market share, business scale and brand influence in the field of oncology medical services will be further expanded and improved
.
It is worth noting that this is not the first time Yibai Pharmaceutical has acquired a hospital
.
In 2017, Yibai Pharmaceutical issued an announcement stating that it would acquire 90% of the equity of the hospital held by Fulin Group at a consideration of 135 million yuan
.
In addition, prior to this, Yibai Pharmaceutical also issued an announcement stating that it would acquire a 32.
5% stake in Huainan Chaoyang Hospital Management Co.
, Ltd.
for 260 million yuan and increase the capital of the hospital management company for 350 million yuan
.
In addition to Yibai Pharmaceutical, in fact, with the continuous introduction of supportive policies by the state in recent years, social forces are encouraged to invest in hospitals
.
In order to penetrate into the new pharmaceutical market, the cases of pharmaceutical companies buying hospitals abound
.
Many companies such as Fuxing Medicine, Sharp Aisi, Kangzhi Pharmaceutical, Aier Ophthalmology and many other companies have issued announcements announcing that they will acquire relevant hospital assets
.
According to the "2020 China Hospital M&A Report" issued by a think tank in the medical field, there will be 45 hospital M&A projects in 2020, 748 target hospitals, and M&A transactions worth 11.
29 billion yuan.
Private hospitals have become the main battlefield for M&A financing.

.
Industry analysts believe that, according to current trends, as pharmaceutical companies continue to look for profit growth points, investment in medical care has become a trend
.
However, it should be noted that for pharmaceutical companies, the pros and cons of buying hospitals coexist
.
After all, hospitals need more refined management, and they also need to invest in greater costs.
Once their own strength can't support it, operations will become difficult
.
It is reported that in the past two years, more and more companies have stopped acquiring hospital businesses, or even reduced their holdings and sold them
.
According to incomplete statistics, in 2020, there will be more than 10 listed companies on the A-share market that have sold hospitals
.
Most of them stem from operating performance and asset pressure
.
Therefore, for pharmaceutical companies that want to enter the market, they still need to carefully consider and carefully deploy
.